AbbVie recently announced positive results for upadacitinib, a small molecule Janus Kinase (JAK) inhibitor, in a phase 3 clinical trial of patients with rheumatoid arthritis (RA). According to AbbVie, upadacitinib met all primary and secondary endpoints in the study, including superiority versus adalimumab, the anti-TNFα antibody that Abbvie markets as Humira®.

As we previously reported, Abbvie has recently reached global settlements with Samsung Bioepis and Amgen, the makers of two adalimumab biosimilars, that reportedly allow the two companies to begin marketing their biosimilar products in Europe in October 2018 and in the United States in January and June 2023, respectively.

AbbVie also reports that Phase 3 trials of upadacitinib in rheumatoid arthritis, psoriatic arthritis and Crohn’s disease are ongoing and that it is investigating the drug to treat ulcerative colitis, ankylosing spondylitis, atopic dermatitis and giant cell arteritis.

Featured Editor

Updated Guide to the Biosimilars Patent Dance

In-house attorneys and executives can request a gratis copy of Goodwin's updated Guide to the Biosimilars Patent Dance

Biosimilars Regulatory IP Guide

Biosimilars: A Guide to Regulatory and Intellectual Property Issues

Subscribe

Big Molecule Watch Monthly DigestMonthly Digest provides analyses on regulatory issues, litigation, legislation, and other news in the ever-developing world of biosimilars. Subscribe>>

Get Real Time Blog PostsYou will receive a verification email once you submit this form to activate your real time Feedburner email subscription to Goodwin Procter - Big Molecule Watch Blog. Subscribe>>